视网膜疾病药物市场规模、份额、成长分析（按疾病、疾病类型、治疗技术、给药途径、最终用户和地区）- 产业预测，2025 年至 2032 年

预计 2022 年全球视网膜疾病治疗市场价值将达到 118 亿美元，到 2031 年将成长至 256.3 亿美元，预测期内（2024-2031 年）的复合年增长率为 9.0%。

全球视网膜疾病治疗市场正经历显着成长，这主要得益于视网膜疾病盛行率的不断上升，目前全球超过2.53亿人受其困扰。这个日益严重的问题给医疗保健系统带来了越来越大的压力，尤其是在老龄化社会持续扩大、视力障碍主要集中在50岁以上人群的情况下。视网膜疾病盛行率的上升，加上糖尿病盛行率的上升，尤其是在新兴市场，进一步加剧了这项挑战。然而，随着专门从事视网膜疾病治疗的专业医疗保健专业人员的涌入以及各国报销体系的加强，预计市场将受益，这将为更广泛地获得先进的视网膜治疗疗法和创新的解决方案铺平道路。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2023年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

视网膜疾病治疗市场规模（依疾病类型划分）及复合年增长率（2024-2031）

• 市场概览
• 黄斑部病变
• 糖尿病眼科疾病
• 视网膜剥离
• 视网膜母细胞瘤
• 黄斑皱纹
• 黄斑裂孔
• 漂浮物

视网膜疾病治疗药物市场规模（依疾病类型及复合年增长率）（2024-2031）

• 市场概览
• 遗传学
• 年龄

视网膜疾病药物市场规模（依治疗技术及复合年增长率） (2024-2031)

• 市场概览
• 雷射
• 冷冻
• 植入
• 缩排
• 气动视网膜固定术
• 巩膜扣带术
• 玻璃体切除手术

视网膜疾病治疗市场规模（依给药途径及复合年增长率）（2024-2031）

• 市场概览
• 口服
• 外用
• 玻璃体内注射
• 其他的

视网膜疾病治疗药物市场规模（按最终用户和复合年增长率划分）（2024 年至 2031 年）

• 市场概览
• 医院
• 门诊手术中心
• 家庭医疗保健
• 其他的

视网膜疾病治疗市场规模（依通路及复合年增长率）（2024-2031）

• 市场概览
• 直接竞标
• 医院药房
• 零售药局
• 网路药局
• 其他的

视网膜疾病治疗药物市场规模（按地区）及复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益年比比较（2021-2023年）

主要企业简介

• Regeneron Pharmaceuticals, Inc.（USA）
• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• Allergan（part of AbbVie）（USA）
• Bayer AG（Germany）
• Oculis（Switzerland）
• REGENXBIO Inc.（USA）
• Adverum Biotechnologies, Inc.（USA）
• Kodiak Sciences Inc.（USA）
• EyePoint Pharmaceuticals, Inc.（USA）
• Apellis Pharmaceuticals, Inc.（USA）
• Iveric Bio, Inc.（USA）（Acquired by Astellas）
• Annexon Biosciences（USA）
• Hemera Biosciences（USA）（Acquired by Roche）
• Gyroscope Therapeutics（UK）（Acquired by Novartis）
• Graybug Vision, Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Ocuphire Pharma, Inc.（USA）
• Lineage Cell Therapeutics, Inc.（USA）
• Ocugen, Inc.（USA）

结论和建议

Global Retinal Disease Therapeutics Market size was valued at USD 11.8 billion in 2022 and is poised to grow from USD 12.86 billion in 2023 to USD 25.63 billion by 2031, growing at a CAGR of 9.0% during the forecast period (2024-2031).

The global retinal disease therapeutics market is experiencing significant growth, driven by the rising prevalence of retinal disorders, which currently affect over 253 million individuals worldwide. This burgeoning issue is putting increasing pressure on healthcare systems, particularly as the aging population continues to expand, with a notable concentration of vision impairment among those over 50 years old. The escalating incidence of retinal diseases, especially in the context of rising diabetes rates in emerging markets, is further compounding the challenge. However, the market is projected to benefit from an influx of specialized healthcare professionals dedicated to retinal disease treatment and enhanced reimbursement frameworks in multiple countries, paving the way for expanding access to advanced therapies and innovative solutions in retinal care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Disease Therapeutics Market Segments Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Disease Therapeutics Market

The increasing incidence of eye-related disorders, particularly in more developed nations, is a significant factor propelling the global market for retinal disease therapeutics. A substantial number of individuals worldwide experience conditions such as diabetic retinopathy and age-related macular degeneration (AMD), underscoring the urgent need for effective treatments. As more individuals become aware of these conditions through enhanced health education initiatives, particularly in developing areas, there is a greater emphasis on seeking early intervention to avoid vision loss. This growing awareness and demand for innovative therapeutic solutions are anticipated to further stimulate advancements and expansion within the retinal therapeutics market.

Restraints in the Global Retinal Disease Therapeutics Market

The global retinal disease therapeutics market faces several challenges that may hinder its growth. High expenses associated with retinal treatment therapies can limit patient accessibility and adoption. Moreover, patients often report experiencing short-term side effects, along with potential long-term complications like infections and inflammation following procedures such as laser eye surgery. The risk of unintentional scleral perforation during specific surgical techniques, such as pneumatic retinopexy, may further deter patient willingness to undergo treatment. Additionally, inadequate healthcare infrastructure in developing regions poses a significant obstacle to the advancement of the retinal disease therapeutics market.

Market Trends of the Global Retinal Disease Therapeutics Market

The Global Retinal Disease Therapeutics market is poised for significant growth, driven by the emergence of advanced technologies, particularly in retinal gene therapy. Innovations such as Luxturna, which targets the RPE65 gene mutation to treat inherited conditions like Leber's congenital amaurosis, underline a transformative shift in therapeutic approaches. As several promising retinal gene therapies are currently undergoing clinical trials using recombinant viruses, their anticipated approval and market entry are set to further enhance treatment options. Between 2022 and 2028, this advancement in gene therapy is projected to significantly expand the market, catering to the increasing demand for effective solutions for retinal disorders.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Retinal Disease Therapeutics Market Size by Disorder & CAGR (2024-2031)

• Market Overview
• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters

Global Retinal Disease Therapeutics Market Size by Disorder Type & CAGR (2024-2031)

• Market Overview
• Genetic
• Age Related

Global Retinal Disease Therapeutics Market Size by Treatment Techniques & CAGR (2024-2031)

• Market Overview
• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Global Retinal Disease Therapeutics Market Size by Route Of Administration & CAGR (2024-2031)

• Market Overview
• Oral
• Topical
• Intravitreal
• Others

Global Retinal Disease Therapeutics Market Size by End-Users & CAGR (2024-2031)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Others

Global Retinal Disease Therapeutics Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Retinal Disease Therapeutics Market Size & CAGR (2024-2031)

• North America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (part of AbbVie) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oculis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio, Inc. (USA) (Acquired by Astellas)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexon Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hemera Biosciences (USA) (Acquired by Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gyroscope Therapeutics (UK) (Acquired by Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations